Overnight Continuous Saline Bladder Irrigation After En Bloc Resection of Bladder Tumor Does Not Improve Oncological Outcomes in Patients Who Have Received Intravesical Chemotherapy

Yongjun Yang†, Chao Liu†, Xiaoting Yan†, Jiawei Li† and Xiaofeng Yang†,2*

† First Clinical Medical College, Shanxi Medical University, Taiyuan, China, 2 Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China

Objective: To evaluate the safety and efficacy of overnight continuous saline bladder irrigation (CSBI) for patients who have received thulium laser en bloc resection of bladder tumor (TmLRBT) combined with immediate intravesical chemotherapy previously.

Methods: From October 2014 to June 2018, 235 patients with newly diagnosed non-muscle invasive bladder cancer (NMIBC) were included in this retrospective study. All patients received intravesical instillation of pirarubicin immediately after TmLRBT. The patients were divided into two groups according to the duration of postoperative bladder irrigation with normal saline. After immediate intravesical chemotherapy, patients in group 1 received overnight CSBI, while patients in group 2 did not receive overnight CSBI. Data on the time of initial tumor recurrence, recurrence-free survival (RFS) and progression-free survival (PFS) rates, and perioperative complications were collected and analyzed.

Results: Of 235 included patients (129 in group 1 and 106 in group 2), the median follow-up periods were 42 and 38 months, respectively. There were no significant differences in patients’ baseline characteristics between the two groups. The RFS rates of patients in group 1 were 90.7, 82.7, and 76.8% at the end of the first, third, and fifth years, while the corresponding RFS rates of patients in group 2 were 87.7, 78.9, and 73.3%, respectively. Four patients in group 1 and five patients in group 2 experienced tumor progression. No significant differences between the two groups were observed in the time of initial tumor recurrence, recurrence-free survival (RFS) and progression-free survival (PFS) rates, and perioperative complications were collected and analyzed.

Conclusions: For patients with NMIBC who have previously received TmLRBT combined with immediate intravesical chemotherapy, overnight CSBI may not improve oncological outcomes and reduce perioperative complications.

Keywords: non-muscle invasive bladder cancer, en bloc resection, continuous saline bladder irrigation, intravesical chemotherapy, recurrence
INTRODUCTION

Bladder cancer (BC) is the tenth most common cancer disease worldwide with 474,000 new incident cases and 197,000 deaths annually, and it is also the second most common malignant disease of the urinary system after prostate cancer (1). Approximately 75% of newly diagnosed BC presents as malignant lesions confined to the mucosa or submucosa, which are collectively referred to as non-muscle invasive bladder cancer (NMIBC) (2). For these patients, transurethral resection of bladder tumor (TURBT) combined with individualized intravesical chemotherapy or immunotherapy that is tailored to tumor risk stratification is recommended as the routine treatment model by the major international guidelines (2–5). However, piecemeal resection of tumor tissue in conventional TURBT results in exfoliated tumor cell dissemination and seeding, which goes against the recognized principle of oncological surgery and partly contributes to increasing the out of field recurrence (6, 7).

Initially, after transurethral tumor resection, continuous saline bladder irrigation (CSBI) was used to prevent the formation of blood clots and achieve excellent hemostasis. Meanwhile, in theory, CSBI can flush out exfoliated tumor cells effectively and prevent them from implanting in the bladder mucosa, thereby reducing the risk of tumor recurrence after conventional resection (8). However, CSBI has no therapeutic effect on the residual tumors at the initial resection site, so it is necessary to perform high-quality and complete tumor resection to make sure that the tumor specimens contain the lamina propria and superficial muscular layer (9).

In the past decade, en bloc resection of bladder tumor (ERBT) served as a valuable alternative technique that has obtained increasing interest among urologists worldwide (10). As a “no touch” surgical technique for the treatment of NMIBC, ERBT shows the potential to minimize the number of exfoliated tumor cells and reduce the risk of tumor cell reimplantation. The use of thulium laser as the energy source for ERBT does not generate high-frequency current and has excellent hemostatic effect. Therefore, the incidence of perioperative complications, such as obturator nerve reflex (ONR), bladder perforation (BP), and acute bleeding will be reduced (11). Then, we tested the hypothesis that overnight CSBI has little effect on improving oncological outcomes and reducing the incidence of perioperative complications for patients with NMIBC who have received thulium laser en bloc resection of bladder tumor (TmLRBT) combined with immediate intravesical chemotherapy.

PATIENTS AND METHODS

Patients
From October 2014 to June 2018, all patients with newly diagnosed NMIBC, who underwent a TmLRBT combined with immediate intravesical instillation of pirarubicin were retrospectively included. Cystoscopy, ultrasonography, intravenous pyelography, and computed tomography were performed to select the appropriate patients before TmLRBT. The inclusion criteria were as follows: 1) patients who underwent TmLRBT successfully without switching to conventional TURBT; 2) patients were diagnosed with NMIBC for the first time; 3) detrusor muscle was contained in the tumor specimens. The exclusion criteria were as follows: 1) preoperative examinations revealed distant metastasis or pelvic lymph node metastasis; 2) carcinoma in situ (CIS) and upper urinary tract neoplasms were accompanied; 3) the intact tumor specimens were cut into two or three parts longitudinally in the bladder before being retrieved; 4) histopathological analysis of the tumor specimens showed that the muscle layer of the bladder was invaded. This study protocol was approved by the Ethics Committee of the First Hospital of Shanxi Medical University. All patients were informed and agreed to participate in the study.

Surgical Procedure
The surgical procedure of white light cystoscopy-assisted TmLRBT was performed by the same urologist with rich experience in endoscopy. All patients were placed in a lithotomy position under combined spinal and epidural anesthesia. Sterile normal saline was used for continuous bladder irrigation, and the Revolix™ thulium laser system (LISA Laser Products, Lindau-Kattenburg, Germany) was used as the energy source during TmLRBT. Firstly, the urologist examined the entire bladder mucosa thoroughly and recorded the tumor location, number, size, and appearance. Then, a circular mucosal incision was made at a safe distance of 5–10 mm from the base of the tumor tissue, and the visible blood vessels near the tumor tissue were coagulated and blocked at the same time. At the circular incision line, the urologist first made a vertical incision from the bladder mucosa to the deep muscular layer and then removed the whole tumor tissue by vapor resection with the thulium laser and blunt dissection with the tip of the resectoscope. In order to minimize the cautery artifacts of the tumor specimens, laser vapor resection was mainly used to cut off the muscle fibers around the tumor. Finally, the intact tumor specimens were retrieved with an Ellick’s evacuator via out sheath of the resectoscope. For the larger-size tumor specimens, an additional medical device, such as laparoscopic forceps, was required to complete the work.

Intravesical Chemotherapy
Immediate intravesical chemotherapy with 30 mg pirarubicin was administered within 6 h after TmLRBT. The duration of pirarubicin in the bladder was 1 h, and then patients in group 1 received overnight CSBI (2,000 ml/h for first 1 h, then 1,000 ml/h for 3 h, and then 250 ml/h for 12 to16 h) after intravesical chemotherapy, while patients in group 2 did not receive.

Abbreviations: BC, Bladder cancer; NMIBC, Non-muscle invasive bladder cancer; TURBT, Transurethral resection of bladder tumor; CSBI, Continuous saline bladder irrigation; ERBT, En bloc resection of bladder tumor; ONR, Obturator nerve reflex; BP, Bladder perforation; TmLRBT, Thulium laser en bloc resection of bladder tumor; CIS, carcinoma in situ; EAU, European Association of Urology; WHO, World Health Organization; RFS, recurrence-free survival; PFS, progression-free survival; MMC: mitomycin C.
overnight CSBI. After discharge from the hospital, patients with intermediate- and high-risk NMIBC received maintenance intravesical chemotherapy with pirarubicin for one year. The detailed scheme of intravesical instillation of pirarubicin was once a week for 8 weeks, followed by monthly intravesical chemotherapy to 12 months. Based on the European Association of Urology (EAU) guidelines, a second transurethral resection was performed in patients with T1 and/or high-grade bladder tumor (12).

Follow-Up Strategies
Patients with low-risk NMIBC were followed up every 3 months in the first year, every 6 months in the second year, and then once a year. For patients with intermediate- and high-risk NMIBC, the follow-up strategy was every 3 months for the first two years, then every 6 months until the fifth year, and then once a year. Routine examination items included ultrasonography, urine cytology, and cystoscopy.

The time of initial tumor recurrence was defined as the time interval between TmLRBT and the date of initial tumor recurrence. When cystoscopy showed space-occupying lesions in the bladder, tumor recurrence should be considered. Tumor progression was defined as an increase in pathological stage. All recurrent and progressive tumor lesions were further confirmed by histopathological assessment. Histological grade and pathological stage of the tumor specimens were evaluated according to the 2004 World Health Organization (WHO) grading system and the 2009 version of TNM staging system, respectively.

Statistical Analysis
Continuous data were expressed as median and tested using unpaired t-test. Qualitative data were described as numbers and percentages and compared through Chi-square test or Fisher’s exact test. Continuous data were expressed as median and tested using unpaired t-test. Qualitative data were described as numbers and percentages and compared through Chi-square test or Fisher’s exact test. The patients’ baseline characteristics and CSBI were included in multivariate Cox proportional hazard models to determine which variables correlate to recurrence-free survival (RFS). The RFS and progression-free survival (PFS) curves were estimated by the Kaplan–Meier method, and the difference between survival curves was analyzed by the log-rank test. Statistical analysis was performed using GraphPad Prism statistical software package, version 7.0 for Windows and IBM SPSS statistics, version 19.0 for Windows. All tests were two-sided, and statistical significance was reached when the P value < 0.05.

RESULTS
The study population included 254 patients with newly diagnosed NMIBC who received TmLRBT. After reviewing the patients’ clinical data, 19 cases were excluded due to the following reasons: six cases were accompanied with CIS, the intact tumor specimens of eight cases were cut into pieces in the bladder before being retrieved, and five cases switched to conventional TURBT during surgery. The remaining 235 patients were divided into two groups according to the duration of postoperative bladder irrigation with normal saline. Patients in group 1 (n = 129) received overnight CSBI after intravesical chemotherapy, while patients in group 2 (n = 106) did not receive overnight CSBI. The patients’ baseline characteristics in the two groups were compared in terms of age, gender, smoking history, tumor diameter, number, grade and stage, and EAU risk stratification. The results showed that no significant differences existed between the two groups (Table 1).

Median follow-up period was 42 months (range 5–65 months) in group 1 and 38 months (range 5–63 months) in group 2. Twenty-six (20.2%) cases in group 1 and twenty-five (23.6%) cases in group 2 developed tumor recurrence during the follow-up period. In group 1, the RFS rates were 90.7, 82.7, and 76.8% at the end of the first, third, and fifth years. In group 2, the RFS rates were 87.7, 78.9, and 73.3% at the end of the first, third, and fifth years, respectively. The Kaplan–Meier curve of the RFS rate of all patients showed no significant difference between the two groups (log-rank test: P = 0.51) (Figure 1A). The RFS rates of patients with low-, intermediate- and high-risk NMIBC also did not reach a significant difference between the two groups (log-rank test: P = 0.68, 0.74 and 0.67, respectively) (Figures 1B–D). In multivariate analysis, overnight CSBI was not an independent predictor of RFS (HR 0.76, P = 0.357) (Table 2).

The median period of initial tumor recurrence was 13 months in group 1 and 12 months in group 2, and no significant difference was observed between the two groups (unpaired t-test: P = 0.96). Four (3.1%) cases in group 1 and five (4.7%) cases in group 2 developed tumor progression during the follow-up period.

| Characteristics | Group 1 (n = 129) | Group 2 (n = 106) | P     |
|-----------------|------------------|------------------|-------|
| Age (year)      | 66 (24–84)       | 65.5 (38–82)     | 0.62  |
| Gender          |                  |                  |       |
| Male            | 103 (79.84%)     | 83 (78.30%)      | 0.87  |
| Female          | 26 (20.16%)      | 23 (21.70%)      |       |
| Smoking history |                  |                  | 0.86  |
| Current         | 58 (44.96%)      | 44 (41.51%)      |       |
| Prior           | 36 (27.91%)      | 32 (30.19%)      |       |
| Never           | 35 (27.13%)      | 30 (28.30%)      |       |
| Tumor diameter (cm) |              |                  | 0.89  |
| 1.0–2.0 cm      | 90 (69.77%)      | 75 (70.75%)      |       |
| 2.0–3.0 cm      | 39 (30.23%)      | 31 (29.25%)      |       |
| Tumor number    |                  |                  | 0.68  |
| Single          | 84 (65.12%)      | 72 (67.92%)      |       |
| Multiple        | 45 (34.88%)      | 34 (32.08%)      | 0.51  |
| Grade (WHO 2004) |              |                  |       |
| Low-grade       | 76 (58.91%)      | 57 (53.77%)      | 0.87  |
| High-grade      | 53 (41.09%)      | 49 (46.23%)      |       |
| T stage         |                  |                  |       |
| Ta              | 106 (82.17%)     | 86 (81.13%)      | 0.93  |
| T1              | 23 (17.83%)      | 20 (18.87%)      |       |
| EAU risk stratification |   |                  |       |
| Low-risk        | 37 (28.68%)      | 28 (26.42%)      |       |
| Intermediate-risk |              |                  |       |
| High-risk       | 62 (48.06%)      | 53 (50.00%)      |       |
|                  | 30 (23.26%)      | 25 (23.58%)      |       |

WHO, World Health Organization; EAU, European Association of Urology.
There was no significant difference in PFS rates between the two groups (log-rank test: \( P = 0.50 \)) (Figure 2).

Perioperative complications were recorded in all 235 patients. Based on the modified Clavien classification system for surgical complications (13), only Grade I complications happened in the two groups. The incidence of Grade I complications were 9.3\% (12/129) and 12.3\% (13/106) in group 1 and group 2, respectively. Although the incidence of complications in group 1 was less, there was no significant difference between the two groups (Fisher’s exact test: \( P = 0.53 \)). No patient experienced ONR and BP during operation (Table 3).

**DISCUSSION**

The well-known principle of oncological surgery is to resect the tumor tissue in one piece with negative surgical margins and prevent iatrogenic tumor cells scattering and local implantation. However, during conventional TURBT, the tumor tissue is resected piece by piece from the exophytic part of the tumor to
TABLE 3 | Perioperative complications.

|                  | Group 1 (n = 129) | Group 2 (n = 106) | P  |
|------------------|-------------------|-------------------|----|
| Obturator nerve reflex | 0                 | 0                 | –  |
| Bladder perforation   | 0                 | 0                 | –  |
| Complications        |                   |                   | 0.53 |
| Grade I              | 12 (9.30%)        | 13 (12.26%)       |    |
| ≥Grade II           | 0                 | 0                 |    |

The function of CSBI is to achieve excellent hemostasis and remove blood clots in the bladder. Meanwhile, continuous bladder irrigation after tumor resection can wash away exfoliated tumor cells and reduce the risk of tumor cell reimplantation in the injured bladder mucosa (21). However, CSBI has no therapeutic effect on the residual tumors at the initial resection site. Then, in order to achieve the effect of postoperative bladder irrigation to reduce tumor recurrence, the prerequisite is high quality and complete resection. Unlike ERBT using electrical current as the energy source, no high-frequency current is generated during TmLRBT. Combined with more precise and controllable procedure of tumor resection, ONR and BP can be avoided (22). After surgery, patients can receive intravesical chemotherapy immediately without being restricted by perioperative complications, such as acute bleeding and BP. Thulium laser, as a diode pumped solid-state laser, works in continuous fashion at the wavelength of 2,013 nm and the penetration depth of 250 μm. Compared with pulsed holmium laser, ERBT using thulium laser as the energy source makes tumor resection more precise and controllable, and the hemostatic effect is excellent (23). Due to its excellent hemostatic effect, bladder irrigation may not be required after surgery to prevent the formation of blood clots in the bladder. In this trial, the results indicated that there were no significant differences in oncological outcomes and perioperative complications between patients who received overnight CSBI or not. Therefore, for well-selected patients with newly diagnosed NMIBC, TmLRBT combined with immediate intravesical chemotherapy can be performed in the day-surgery unit without the need of overnight CSBI. This is a better mode of allocating medical resources, which alleviates the logistical pressure caused by the expansion of the waiting number to a certain extent. It is also a process of reducing health-care costs and has a positive impact on medical expenses (24).

The main limitation of the trial is its retrospective design and relatively small patient population. However, we believe that our preliminary findings are very meaningful for urologists and patients with NMIBC. For patients with newly diagnosed NMIBC, urologists can choose to perform TmLRBT as day-surgery operation on them to shorten the waiting time outside the hospital, and then reduce the patient’s nervousness related to waiting outside the hospital (25). Further prospective randomized controlled trials with more patients are needed to confirm our results. Second, thulium is a less commonly used laser energy source in transurethral tumor resection, and ERBT is less commonly
performed than conventional TURBT. Due to the excellent hemostatic effect of thulium and the theoretical benefits of ERBT, TmLRBT may gain more and more interest among urologists. Third, although pirarubicin is not as widely used in intravesical chemotherapy as gemcitabine or mitomycin C (MMC), in a systematic review, indirect comparisons could not detect any differences in efficacy between MMC and pirarubicin (26).

CONCLUSIONS

For patients with newly diagnosed NMIBC, after TmLRBT combined with immediate intravesical chemotherapy, overnight CSBI cannot improve oncological outcomes and reduce the incidence of perioperative complications. Therefore, TmLRBT may be performed as day-surgery operation for well-selected patients.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol (2019) 5:1749–68. doi: 10.1001/jamaoncol.2019.2996
2. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol (2019) 76:339–57. doi: 10.1016/j.eururo.2019.08.016
3. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2020) 18:329–54. doi: 10.6004/jnccn.2020.0011
4. Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zotta A, Fairey A, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J (2015) 9:E690–704. doi: 10.5489/cuaj.3320
5. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol (2016) 196:1021–9. doi: 10.1016/j.juro.2016.06.049
6. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid HA, Palou J, et al. Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered? Eur Urol Focus (2018) 4:525–8. doi: 10.1016/j.euf.2018.07.023
7. Bălan G, Gavilete PA, Georgescu DA, Ene CV, Bulai CA, Păunescu MA, et al. Bipolar en bloc tumor resection versus standard monopolar TUR-BT - which is the best way to go in non-invasive bladder cancer? Rom J Morphol Embryol (2018) 59:773–80.
8. Zhou Z, Zhao S, Lu Y, Wu J, Li Y, Gao Z, et al. Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors. World J Urol (2019) 37:1075–84. doi: 10.1007/s00345-019-02628-7
9. Kramer MW, Altieri V, Hurle R, Lusuardi L, Merseburger AS, Rassweiler J, et al. Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. Eur Urol Focus (2017) 3:567–76. doi: 10.1016/j.euf.2016.12.004
10. Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, et al. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol (2020) 78:546–69. doi: 10.1016/j.eururo.2020.04.059
11. Territo A, Bevilacqua G, Meneghetti I, Mercade A, Breda A. En bloc resection of bladder tumors: indications, techniques, and future directions. Curr Opin Urol (2020) 30:421–7. doi: 10.1097/MOU.0000000000000737
12. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 64:639–53. doi: 10.1016/j.eururo.2013.06.003
13. De Nunzio C, Fraco G, Cindolo L, Autorino R, Ciccone A, Perdonà S, et al. Transurethral resection of the bladder (TURB): analysis of complications using a modified Clavien system in an Italian real life cohort. Eur J Surg Oncol (2014) 40:90–5. doi: 10.1016/j.ejso.2013.11.003
14. Xu S, Tan S, Wu T, Gu J, Xu L, Che X. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer. Lasers Med Sci (2020) 35:1695–701. doi: 10.1007/s11013-020-02960-0
15. Liang H, Yang T, Wu K, He D, Fan J. En bloc resection improves the identification of muscularis mucosa in non-muscle invasive bladder cancer. World J Urol (2019) 37:2677–82. doi: 10.1007/s00345-019-02672-3
16. Xu H, Ma J, Chen Z, Yang J, Yuan H, Wang T, et al. Safety and Efficacy of En Bloc Transurethral Resection With 1.9 µm Vela Laser for Treatment of Non-Muscle-invasive Bladder Cancer. Urology (2018) 113:246–50. doi: 10.1016/j.urology.2017.11.030
17. Kramer MW, Rassweiler JJ, Klein J, Martov A, Baykov N, Lusuardi L, et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): A European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol (2015) 33:1937–43. doi: 10.1007/s00345-015-1568-6
18. Li K, Xu Y, Tan M, Xia S, Xu Z, Xu D. A retrospective comparison of thulium laser en bloc resection of bladder tumor and plasmakinetic transurethral resection of bladder tumor in primary non-muscle invasive bladder cancer. Lasers Med Sci (2019) 34:85–92. doi: 10.1007/s10103-018-2604-8

ETHICS STATEMENT

The study was approved by the Ethics Committee of the First Affiliated Hospital of Shanxi Medical University (2011033/2011) and conducted according to the principles of the Declaration of Helsinki.

AUTHOR CONTRIBUTIONS

YY designed the clinical study, collected and analyzed the clinical data, and wrote the manuscript. CL analyzed and interpreted the patient data. XTY and JL collected and analyzed the clinical data. XYF designed the study, supervised the research, contributed to the experimental discussion, and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported by the National Natural Science Foundation of China Grants (81172444 to XYF).
19. Zhang KY, Xing JC, Li W, Wu Z, Chen B, Bai DY. A novel transurethral resection technique for superficial bladder tumor: retrograde en bloc resection. World J Surg Oncol (2017) 15:125. doi: 10.1186/s12957-017-1192-6

20. Tao W, Sun C, Yao Q, Fu K, Shan Y, Zhang Y, et al. The clinical study of en bloc transurethral resection with 980 nm laser for treatment of primary non-muscle invasive bladder cancer. J Xray Sci Technol (2020) 28:563–71. doi: 10.3233/XST-190616

21. Onishi T, Sugino Y, Shibahara T, Masui S, Yabana T, Sasaki T. Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU Int (2017) 119:276–82. doi: 10.1111/bju.13599

22. Wang W, Liu H, Xia S. Thulium laser treatment for bladder cancer. Asian J Urol (2016) 3:130–3. doi: 10.1016/j.ajur.2016.05.002

23. Enikeev D, Shariat SF, Taratkin M, Glybochko P. The changing role of lasers in urologic surgery. Curr Opin Urol (2020) 30:24–9. doi: 10.1097/MOU.0000000000000695

24. Sloan FA, Yashkin AP, Akushevich I, Inman BA. The Cost to Medicare of Bladder Cancer Care. Eur Urol Oncol (2019) 3:515–22. doi: 10.1016/j.euo.2019.01.015

25. Tan WS, Teo CH, Chan D, Ang KM, Heinrich M, Feber A, et al. Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed-methods approach. BJU Int (2020) 125:669–78. doi: 10.1111/bju.15008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Liu, Yan, Li and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.